pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Ophthalmology · news · pharmadog
← back to Ophthalmology
News · Ophthalmology
406
stories
Jul 28, 26
Claris collects $118M to take eye drop into pivotal testing next year
endpoints
Jul 28, 26
An eye drug biotech banks $118M and stocks its executive suite
biopharma dive
Jul 28, 26
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
globenewswire health
Jul 28, 26
STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
stat
Jul 27, 26
‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drug
fiercebiotech
Jul 27, 26
Yarrow to begin trading as it targets Graves; FDA approves Otsuka's ADHD pill
endpoints
Jul 27, 26
MapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout
biospace
Jul 27, 26
FDA scientists question Capricor data; Legend CEO steps down
biopharma dive
Jul 27, 26
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
biospace
Jul 27, 26
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
biopharma dive
Jul 27, 26
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
biospace
Jul 27, 26
Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug
fiercebiotech
Jul 27, 26
FDA has recommitted to adcomms—but to what end?
biospace
Jul 23, 26
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
biospace
Jul 23, 26
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
fiercebiotech
Jul 22, 26
Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
biospace
Jul 22, 26
US ‘eroding’ lead in rare diseases a matter of national security: Report
biospace
Jul 22, 26
Job dissatisfaction and health care access uncertainty grows in the U.S., new study finds
stat
Jul 22, 26
STAT+: ‘Cochlear implant for blindness’ debuts in Europe, could launch in U.S. in 2027
stat
Jul 22, 26
As Maui recovers from devastating fires, a study offers vision for new rural health model
stat
Jul 21, 26
Opinion: Pete Hegseth, ‘The Odyssey,’ and the testosterone myth
stat
Jul 21, 26
Is there an exodus underway at Epic?
stat
Jul 21, 26
THC drinks are sold beside sodas, iced tea, and even chocolate milk, often in violation of state laws
stat
Jul 21, 26
Roche taps Foundation Medicine’s chief as new North America Diagnostics lead, creates new commercial role
fiercebiotech
Jul 20, 26
Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvals
biospace
Jul 20, 26
BMS expands AI footprint with Nvidia, aiming for ‘most powerful AI factory in life sciences’
fiercebiotech
Jul 20, 26
How Kyverna rode CAR T’s autoimmune wave to the FDA’s door
biospace
Jul 19, 26
Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax
fiercebiotech
Jul 18, 26
‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
fiercebiotech
Jul 16, 26
Chutes & Ladders—Cue lines up new CMO and research head
fiercebiotech
← prev
page 11 of 14
next →